CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting

Core Insights - Arcellx, Inc. (NASDAQ:ACLX) is recognized as a promising investment opportunity due to its CAR-T therapy, which is expected to perform well in the multiple myeloma market [2][3] Financial Performance - For Q3 2025, Arcellx reported a net loss of $55.8 million, an increase from $25.9 million in Q3 2024 [4] - The company ended the quarter with $576 million in cash, providing operational runway until 2028 [4] - Collaboration revenue significantly decreased from $26 million in Q3 2024 to $4.9 million in Q3 2025 due to the completion of dosing in the iMMagine-1 trial [4] Market Position and Growth Potential - The management is optimistic about capturing a significant share of the second-line to third-line (2L-3L) global multiple myeloma market, particularly in large healthcare enterprises and academic centers [3] - Upcoming data presentations at the ASH meeting are anticipated to validate the durability and efficacy of the company's CAR-T therapy, potentially driving stock upside [3] Analyst Sentiment - Morgan Stanley's analyst Judah Frommer maintained a "Buy" rating for Arcellx, citing the safety profile and high potential for minimal residual disease negativity rates of the CAR-T therapy [2]